



## **cobas<sup>®</sup> 8000 modular analyzer series** *Intelligent LabPower - because demanding jobs require intelligent and powerful solutions, now and in the future*

Designed for high volume testing, the **cobas<sup>®</sup> 8000** modular analyzer series reaches new dimensions in high speed, intelligent sample dynamics and workflow improvements whilst still ensuring optimal performance for individual patients. Highest quality & safety standards are met and intelligent sample, reagent and result management further enhances efficiency.

**cobas<sup>®</sup> 8000** modular analyzer series with its flexible modularity offers tailored solutions to meet the changing needs of the laboratory bringing a new dimension in terms of productivity, efficiency, process innovation and consolidation.

The **cobas<sup>®</sup> 8000** modular analyzer series acts intelligently empowering the laboratory to improve trusted services to their customers and to patients.



**cobas<sup>®</sup> 8000** modular analyzer series



Roche Diagnostics Ltd.  
CH-6343 Rotkreuz  
[www.roche.com](http://www.roche.com)

COBAS and LIFE NEEDS ANSWERS  
are trademarks of Roche.  
© 2010 Roche

**cobas<sup>®</sup>**

*Life needs answers*



# MEDICAL CORPS

I N T E R N A T I O N A L F O R U M

Special: COMEDS and its Partnership for Peace Nations

## Operational Medicine



# Aesculap

## Partner of Military Medicine



### Aesculap Surgical Technologies

#### Aesculap offers for military medical services:

- Optimized products
- Complete sets with documentation
- Impact and vibration proof devices and instrument storage
- Long-term packaging
- Already about 5,500 of our articles are registered under NATO stock numbers.

#### SUSi - Aesculap single-use instruments

- Sterile packaging
- Ready for immediate use
- Low weight
- Small packing dimensions
- Environmentally appropriate disposal
- Registered under NATO stock numbers.

**B | BRAUN**  
SHARING EXPERTISE

Aesculap AG · Am Aesculap-Platz · 78532 Tuttlingen/Germany · Phone +49 7461 95-0 · [www.aesculap.de](http://www.aesculap.de)

# Smallpox a re-emerging threat?

Biological weapons are an increasingly serious threat to national security

Advances in synthetic biotechnology increase the likelihood and concern that the smallpox virus might be obtained and used as an agent of bioterrorism.

**“The synthesis of full-length Variola virus genomes and the creation of live orthopoxviruses is now technically feasible”**

WHO Advisory Committee on Variola Virus Research, November 2009

The world has witnessed a knowledge explosion in the life sciences based on an understanding of genes and how they work. This continued advancement of biotechnology increases the availability and weaponization potential of dangerous pathogens.

**“The creation or acquisition of smallpox is well within the technical reach of a determined and well-resourced terrorist....”**

US Department of Homeland Security Bioterrorism Risk Assessment

Smallpox is a highly contagious disease unique to humans caused by the Variola virus. It is easily transmitted from person-to-person and about 30 percent of those who become infected will die. Few other illnesses have had such a profound effect on human health. In the 20th century alone, it is estimated that at least 300 million people have died from smallpox.

Smallpox exhibits the ultimate threat in terms of public health, disruption of social order, economics, national security and governance. In fact, an outbreak involving smallpox,

whether by accidental release or deliberate attack, constitutes a major security threat on a national level which could easily become an international disaster.

In a potential outbreak the military will play a critical role in handling security. In order to have freedom to operate, the troops must be vaccinated as this is the only durable and feasible protection against smallpox. The conventional replicating vaccines are effective but unsafe due to high rates of serious adverse events; these include death and severe disability. This makes them a challenging asset to deploy.

To address the unacceptable side effects of the traditional vaccines, Bavarian Nordic A/S is developing a new non-replicating smallpox vaccine (IMVAMUNE®) for military personnel and first line responders, which has proven to be well tolerated even in people normally contraindicated to the conventional vaccines.

## **Bavarian Nordic – leading in biodefense**

Bavarian Nordic A/S is a leading industrial biotechnology company, developing and producing novel vaccines for the prevention and treatment of life-threatening diseases, targeting unmet medical needs. The development of safe and effective preventative countermeasures against potential biological weapons is Bavarian Nordic's principal area of business.

For further information please visit our website at [www.bavarian-nordic.com](http://www.bavarian-nordic.com)

<sup>1</sup> WHO Advisory Committee on Variola Virus Research, November 2008

<sup>2</sup> Department of Homeland Security Bioterrorism Risk Assessment: A Call for Change, 2008

  
BAVARIAN NORDIC